文献速递头颈与中枢神经肿瘤

2000至2014年美国成人胶质瘤发病率与生存率的种族/民族差异

Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.
PubMed 文献 · JAMA Oncol · 2018-01-01

IMPORTANCE: Glioma is the most commonly occurring malignant brain tumor in the United States, and its incidence varies by age, sex, and race or ethnicity. Survival after brain tumor diagnosis has been shown to vary by these factors.…

要点

  • 非西班牙裔白人胶质母细胞瘤、非胶质母细胞瘤星形细胞瘤和少突胶质细胞肿瘤发病率高于其他种族/民族。
  • 男性胶质母细胞瘤发病率总体比女性高60%。
  • 非西班牙裔白人多种胶质瘤亚型(包括胶质母细胞瘤)生存率低于其他种族/民族,与治疗类型无关。

核心结论

  • 胶质瘤发病率及诊断后1年和5年相对生存率因种族/民族显著不同,非西班牙裔白人发病率更高且生存率更低。

主要发现

  • 非西班牙裔白人胶质母细胞瘤、非胶质母细胞瘤星形细胞瘤和少突胶质细胞肿瘤发病率高于西班牙裔白人(总体低30%)、黑人(总体低52%)、美洲印第安人/阿拉斯加原住民(总体低58%)或亚洲/太平洋岛民(总体低52%)。
  • 大多数肿瘤男性比女性更常见,胶质母细胞瘤差异最大,男性总体高60%。
  • 西班牙裔白人、黑人及亚洲/太平洋岛民之间不同亚型胶质瘤生存率总体相当,但非西班牙裔白人多种肿瘤类型(包括胶质母细胞瘤)生存率较低,与治疗类型无关。

临床怎么用

  • 临床中应关注胶质瘤发病和生存的种族/民族差异,识别未满足的医疗需求。
  • 非西班牙裔白人胶质瘤发病率更高且生存更差,提示需探索潜在风险因素和健康差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Glioma is the most commonly occurring malignant brain tumor in the United States, and its incidence varies by age, sex, and race or ethnicity. Survival after brain tumor diagnosis has been shown to vary by these factors. OBJECTIVE: To quantify the differences in incidence and survival rates of glioma in adults by race or ethnicity. DESIGN, SETTING, AND PARTICIPANTS: This population-based study obtained incidence data from the Central Brain Tumor Registry of the United States and survival data from Surveillance, Epidemiology, and End Results registries, covering the period January 1, 2000, to December 31, 2014. Average annual age-adjusted incidence rates with 95% CIs were generated by glioma histologic groups, race, Hispanic ethnicity, sex, and age groups. One-year and 5-year relative survival rates were generated by glioma histologic groups, race, Hispanic ethnicity, and insurance status. The analysis included 244 808 patients with glioma diagnosed in adults aged 18 years or older. Data were collected from January 1, 2000, to December 31, 2014. Data analysis took place from December 11, 2017, to January 31, 2018. RESULTS: Overall, 244 808 patients with glioma were analyzed. Of these, 150 631 (61.5%) were glioblastomas, 46 002 (18.8%) were non-glioblastoma astrocytomas, 26 068 (10.7%) were oligodendroglial tumors, 8816 (3.6%) were ependymomas, and 13 291 (5.4%) were other glioma diagnoses in adults. The data set included 137 733 males (56.3%) and 107 075 (43.7%) females. There were 204 580 non-Hispanic whites (83.6%), 17 321 Hispanic whites (7.08%), 14 566 blacks (6.0%), 1070 American Indians or Alaska Natives (0.4%), and 5947 Asians or Pacific Islanders (2.4%). Incidences of glioblastoma, non-glioblastoma astrocytoma, and oligodendroglial tumors were higher among non-Hispanic whites than among Hispanic whites (30% lower overall), blacks (52% lower overall), American Indians or Alaska Natives (58% lower overall), or Asians or Pacific Islanders (52% lower overall). Most tumors were more common in males than in females across all race or ethnicity groups, with the great difference in glioblastoma where the incidence was 60% higher overall in males. Most tumors (193 329 [79.9%]) occurred in those aged 45 years or older, with differences in incidence by race or ethnicity appearing in all age groups. Survival after diagnosis of glioma of different subtypes was generally comparable among Hispanic whites, blacks, and Asians or Pacific Islanders but was lower among non-Hispanic whites for many tumor types, including glioblastoma, irrespective of treatment type. CONCLUSIONS AND RELEVANCE: Incidence of glioma and 1-year and 5-year survival rates after diagnosis vary significantly by race or ethnicity, with non-Hispanic whites having higher incidence and lower survival rates compared with individuals of other racial or ethnic groups. These findings can inform future discovery of risk factors and reveal unaddressed health disparities.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ostrom QT, Cote DJ, Ascha M, et al. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. JAMA Oncol. 2018. PMID: 29931168. doi:10.1001/jamaoncol.2018.1789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。